Spots Global Cancer Trial Database for adoptive immunotherapy
Every month we try and update this database with for adoptive immunotherapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors | NCT02757391 | Colorectal Aden... Metastatic Chol... Metastatic Colo... Metastatic Dige... Metastatic Esop... Metastatic Gast... Metastatic Panc... Stage IV Colore... Stage IV Esopha... Stage IV Gastri... Stage IV Pancre... Stage IVA Color... Stage IVB Color... | Adoptive Immuno... Aldesleukin Cyclophosphamid... Laboratory Biom... Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma | NCT01593696 | ALL B Cell Lymphoma Leukemia Large Cell Lymp... Non-Hodgkin Lym... | Anti-Cluster of... | 1 Year - 30 Years | National Institutes of Health Clinical Center (CC) | |
| Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma | NCT01636388 | Hodgkins Lympho... | allogeneic dono... | - 45 Years | New York Medical College | |
| Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant | NCT04815356 | Hairy Cell Leuk... Hairy Cell Leuk... | CD22CART cell i... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma | NCT00324623 | Melanoma (Skin) | Melan-A VLP vac... adoptive immuno... therapeutic aut... cyclophosphamid... fludarabine pho... | 18 Years - 75 Years | Centre Hospitalier Universitaire Vaudois | |
| Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma | NCT00512889 | Melanoma (Skin) | therapeutic aut... Use of an artif... GM-CSF Irradiation of ... | 18 Years - | Dana-Farber Cancer Institute | |
| Trafficking of Indium-III-Labeled Cultured Immune Cells in Patients Undergoing Immunotherapy for Advanced Cancer | NCT00026897 | Neoplasm | Gamma-camera im... Low-risk biopsy | - | National Institutes of Health Clinical Center (CC) | |
| Autologous T Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) Patients | NCT00058656 | Chronic Lymphoc... | Infusion of Act... | 18 Years - | Xcyte Therapies | |
| Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes | NCT02134262 | Relapsed or Ref... | Cyclophosphamid... Dose Level -1 Dose Level 1 Dose Level 2 Dose Level 3 | 20 Years - 70 Years | Jichi Medical University | |
| Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma | NCT00324623 | Melanoma (Skin) | Melan-A VLP vac... adoptive immuno... therapeutic aut... cyclophosphamid... fludarabine pho... | 18 Years - 75 Years | Centre Hospitalier Universitaire Vaudois | |
| Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation | NCT00460629 | Chronic Myeloid... | Application of ... | 18 Years - 60 Years | University Hospital Carl Gustav Carus | |
| ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia | NCT01478074 | Acute Myeloid L... | G-CSF Cytarabine Fludarabine Donor Natural K... ALT-801 | 2 Years - 59 Years | Altor BioScience | |
| Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation | NCT00460629 | Chronic Myeloid... | Application of ... | 18 Years - 60 Years | University Hospital Carl Gustav Carus | |
| Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma | NCT02851784 | Hepatocellular ... | adoptive immuno... MWA | - | Chinese PLA General Hospital | |
| A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients | NCT01588769 | Glioblastoma Mu... | ALECSAT cell ba... | 18 Years - | CytoVac A/S | |
| Allogeneic "Gammadelta T Cells (γδ T Cells)" Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical Trial | NCT04518774 | Hepatocellular ... | Ex-vivo expande... | 18 Years - 65 Years | Beijing 302 Hospital | |
| Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma | NCT01593696 | ALL B Cell Lymphoma Leukemia Large Cell Lymp... Non-Hodgkin Lym... | Anti-Cluster of... | 1 Year - 30 Years | National Institutes of Health Clinical Center (CC) | |
| Trafficking of Indium-III-Labeled Cultured Immune Cells in Patients Undergoing Immunotherapy for Advanced Cancer | NCT00026897 | Neoplasm | Gamma-camera im... Low-risk biopsy | - | National Institutes of Health Clinical Center (CC) | |
| T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant | NCT00048464 | Multiple Myelom... | Infusion of Act... | 18 Years - 70 Years | Xcyte Therapies | |
| Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients | NCT00287131 | Metastatic Mela... | Procedure - Ado... | 18 Years - | Sheba Medical Center | |
| Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT03155191 | Lymphoblastic L... | TBI-1501 | 16 Years - | Takara Bio Inc. | |
| Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation | NCT00460629 | Chronic Myeloid... | Application of ... | 18 Years - 60 Years | University Hospital Carl Gustav Carus | |
| Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma | NCT00512889 | Melanoma (Skin) | therapeutic aut... Use of an artif... GM-CSF Irradiation of ... | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients | NCT01588769 | Glioblastoma Mu... | ALECSAT cell ba... | 18 Years - | CytoVac A/S | |
| Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies | NCT02315612 | NHL Large Cell Lymp... Follicular Lymp... ALL B-All B-precursor ALL Acute Lymphobla... Acute Lymphocyt... B-Non Hodgkin L... B-NHL | CD22-CAR | 3 Years - 39 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
